This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Get started with patient support Co-Pay Savings Program

Co-Pay Savings Program

Your eligible commercially insured patients may pay as little as $0 with the HYMPAVZI Co-Pay Savings Program. Patients can register on HYMPAVZI.com. Terms and conditions apply.*

 Patient resources

Pfizer Hemophilia Connect for HYMPAVZI offers personalized support for eligible patients through a dedicated Patient Case Manager, patient support resources, benefits verification, and information about the insurance coverage process. Eligible patients can call 1-888-733-2030 between 8AM-6PM ET for help.

 Voucher Program

Eligible new patients may receive a free one-time, 4-week supply of HYMPAVZI. Please refer to the Resources page for the Enrollment Form needed for the HYMPAVZI Voucher Program. See full terms and conditions.†

Patient savings program Co-Pay Savings Program

Your eligible commercially insured patients may pay as little as $0 with the HYMPAVZI Co-Pay Savings Program. Patients can register on HYMPAVZI.com. Terms and conditions apply.*

Patient resources Patient resources

Pfizer Hemophilia Connect for HYMPAVZI offers personalized support for eligible patients through a dedicated Patient Case Manager, patient support resources, benefits verification, and information about the insurance coverage process. Eligible patients can call 1-888-733-2030 between 8AM-6PM ET for help.

Patient resources Voucher Program

Eligible new patients may receive a free one-time, 4-week supply of HYMPAVZI. Please refer to the Resources page for the Enrollment Form needed for the HYMPAVZI Voucher Program.
See full terms and conditions.†

*Co-Pay Savings Program Full Terms and ConditionsBy using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Patient must have private insurance with coverage for HYMPAVZI. Offer is not valid for cash paying patients. The value of this co-pay card is limited to $15,000 per calendar year or the amount of your co-pay over 1 year, whichever is less. This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards. This co-pay card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance. This co-pay card is not valid where prohibited by law. The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either. Co-pay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program. Co-pay card will be accepted only at participating pharmacies. This co-pay card is not health insurance. Offer good only in the U.S. and Puerto Rico. Co-pay card is limited to 1 per person during this offering period and is not transferable. No other purchase is necessary. Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires 12/31/2025. No membership fees.

†Voucher Program Full Terms and Conditions

By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms & Conditions described below:
  • You will receive a one-time, 28-day supply of HYMPAVZI. Only eligible new HYMPAVZI patients may use this voucher, and each patient is limited to 1 voucher.
  • By redeeming this voucher, you certify that you are not currently using HYMPAVZI.
  • An original voucher and a valid prescription must be presented to the pharmacy.
  • The voucher will be accepted only at participating pharmacies.‡
  • You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
  • You must be 18 years of age or older or be 18 years of age or older and a caregiver of a HYMPAVZI patient.
  • This voucher is not valid where prohibited by law.
  • This voucher cannot be combined with any other savings, free trial, or similar offers for the specified prescription.
  • This free trial voucher is not health insurance. This free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription.
  • Offer good only in the U.S. and Puerto Rico.
  • No purchase is necessary.
  • Patients have no obligation to continue to use HYMPAVZI.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice. This voucher expires on 12/31/2025.

‡Massachusetts residents may select their pharmacy. Otherwise, this free trial will be supplied through SONEXUS.

HYMPAVZI is a trademark of Pfizer Inc.

Resources

HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0426
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.